



100



Price achieved vs. disease prevalence


There is a negative correlation between reimbursed annual treatment costs achieved at launch and eligible patient numbers.



Note, the analysis covers 67 rare disease products that were evaluated by the Transparency Commission between 2013 and 2023

Price achieved vs. disease prevalence

However, prevalence alone doesn't drive launch pricing. Other factors include ASMR rating, unmet need, availability of comparators, and strength of clinical data.




Note, the analysis covers 67 rare disease products that were evaluated by the Transparency Commission between 2013 and 2023

Price achieved vs. disease prevalence

Waylivra is a noticeable outlier. It was granted an ASMR 4 and achieved a relatively high list price in a market with low-cost standard-of-care.

However, price negotiations lasted 20 months.



Note, the analysis covers 67 rare disease products that were evaluated by the Transparency Commission between 2013 and 2023

Contact our Life Sciences experts to learn more.

CRA Charles River
Associates